Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $187.0 million.

  • Indivior Pharmaceuticals' Operating Expenses fell 922.33% to $187.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $726.0 million, marking a year-over-year increase of 3750.0%. This contributed to the annual value of $919.0 million for FY2024, which is 1427.24% down from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported Operating Expenses of $187.0 million as of Q3 2025, which was down 922.33% from $178.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' 5-year Operating Expenses high stood at $338.0 million for Q2 2024, and its period low was -$460.0 million during Q4 2022.
  • For the 4-year period, Indivior Pharmaceuticals' Operating Expenses averaged around -$13.9 million, with its median value being $16.5 million (2022).
  • Per our database at Business Quant, Indivior Pharmaceuticals' Operating Expenses tumbled by 20222.22% in 2023 and then soared by 30484.85% in 2024.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' Operating Expenses stood at -$460.0 million in 2022, then soared by 59.35% to -$187.0 million in 2023, then skyrocketed by 209.63% to $205.0 million in 2024, then dropped by 8.78% to $187.0 million in 2025.
  • Its Operating Expenses stands at $187.0 million for Q3 2025, versus $178.0 million for Q2 2025 and $156.0 million for Q1 2025.